论文部分内容阅读
新的研究数据表明，Lilly公司的5-HT/去甲肾上腺素再摄取抑制剂(SNRI)类抗抑郁药度洛西汀(duloxetine)可能有助于填补该公司的重磅炸弹级抗抑郁药氟西汀(fluoxetine,Prozac)失去专利保护后留下的空白。研究结果显示，度洛西汀对治疗抑郁症的情绪和躯体症状都有效，使其能够在拥
New data suggest that Lilly’s duloxetine, an 5-HT / norepinephrine reuptake inhibitor (SNRI) -like antidepressant, may help fill the company’s blockbuster antidepressant Fluoxetine (fluoxetine, Prozac) Lost patent left blank. The results show that duloxetine is effective in treating mood and somatic symptoms of depression so that it can be administered